Intel Corporation acquires AI chipmaker Habana Labs for $2 billion

By Nikita Chaurasia  Date: 2019-12-17

Intel Corporation acquires AI chipmaker Habana Labs for $2 billion

US tech giant Intel Corp. announced that it has inked a deal to acquire chip startup Habana Labs, for $2 billion to strengthen its artificial intelligence (AI) portfolio. The move will accelerate efforts of the company in AI silicon market, which is expected to surpass $25 billion by 2024.

Earlier, Intel had confirmed that it would soon deliver Nervana chips, but the latest deal indicates that initial lighthouse accounts would rather choose to make a second attempt with Nervana. The chips are estimated to be incapable of going forward, but Intel is likely to take a few months to explore more options and sideline Nervana.

Habana Labs has secured top standing among startups readying hardware for AI by delivering working hardware with superior performance for both interference and training processing. In September 2018, the chip startup had rolled out Goya chip for interference processing and claimed 3 times better performance benefit over NVIDIA with lower latency. In June 2019, it announced to launch its training chip Gaudi, which was claimed to perform exceptionally with an integrated fabric created following fabric standards to allow scaling to manage massive AI models.

Navin Shenoy, General Manager, Data Platforms Group, Intel, reportedly stated that the acquisition will help to develop the company’s AI strategy, to offer solutions suitable for every performance need, from intelligent edge to data center. Habana will strengthen AI offerings of the company for data center with a superior training processor portfolio and a programming environment based on standards to address increasing AI workloads, he added. 

Habana will be able to offer its technology to large datacenters, which would like to depend upon a big technology firm like Intel, instead of a small startup. Intel may offer its resources for creating a remarkable ecosystem around the company, which is unviable for well-funded startups.

For the record, acquisition of Habana follows previous AI- related investments of Intel in Movidius, Nervana, Altera, and Mobileye.
 

Source credits:

https://www.forbes.com/sites/moorinsights/2019/12/16/intel-acquires-habana-labs-for-2b/#1471cc4b19f9

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...